Structure-based discovery of selective positive allosteric modulators of antagonists for the M2 muscarinic acetylcholine receptor
View/ Open
Author
Korczynska, Magdalena
Clark, Mary J.
Valant, Celine
Xu, Jun
Moo, Ee Von
Albold, Sabine
Weiss, Dahlia R.
Torosyan, Hayarpi
Huang, Weijiao
Lyda, Brent R.
May, Lauren T.
Baltos, Jo-Anne
Sexton, Patrick M.
Kobilka, Brian K.
Christopoulos, Arthur
Shoichet, Brian K.
Sunahara, Roger K.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1073/pnas.1718037115Metadata
Show full item recordCitation
Korczynska, M., M. J. Clark, C. Valant, J. Xu, E. V. Moo, S. Albold, D. R. Weiss, et al. 2018. “Structure-based discovery of selective positive allosteric modulators of antagonists for the M2 muscarinic acetylcholine receptor.” Proceedings of the National Academy of Sciences of the United States of America 115 (10): E2419-E2428. doi:10.1073/pnas.1718037115. http://dx.doi.org/10.1073/pnas.1718037115.Abstract
Subtype-selective antagonists for muscarinic acetylcholine receptors (mAChRs) have long been elusive, owing to the highly conserved orthosteric binding site. However, allosteric sites of these receptors are less conserved, motivating the search for allosteric ligands that modulate agonists or antagonists to confer subtype selectivity. Accordingly, a 4.6 million-molecule library was docked against the structure of the prototypical M2 mAChR, seeking molecules that specifically stabilized antagonist binding. This led us to identify a positive allosteric modulator (PAM) that potentiated the antagonist N-methyl scopolamine (NMS). Structure-based optimization led to compound ’628, which enhanced binding of NMS, and the drug scopolamine itself, with a cooperativity factor (α) of 5.5 and a KB of 1.1 μM, while sparing the endogenous agonist acetylcholine. NMR spectral changes determined for methionine residues reflected changes in the allosteric network. Moreover, ’628 slowed the dissociation rate of NMS from the M2 mAChR by 50-fold, an effect not observed at the other four mAChR subtypes. The specific PAM effect of ’628 on NMS antagonism was conserved in functional assays, including agonist stimulation of [35S]GTPγS binding and ERK 1/2 phosphorylation. Importantly, the selective allostery between ’628 and NMS was retained in membranes from adult rat hypothalamus and in neonatal rat cardiomyocytes, supporting the physiological relevance of this PAM/antagonist approach. This study supports the feasibility of discovering PAMs that confer subtype selectivity to antagonists; molecules like ’628 can convert an armamentarium of potent but nonselective GPCR antagonist drugs into subtype-selective reagents, thus reducing their off-target effects.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877965/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:37067853
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)